GLP-1 RAs Linked to Higher Hair Loss Risk
A large matched cohort study quantifies the association between glucagon-like peptide-1 receptor agonist use and nonscarring alopecia
-
By
-
Kerri Miller
-
February 19, 2026
-
Clinical Scorecard: GLP-1 RAs Linked to Higher Hair Loss Risk
At a Glance
| Category | Detail |
|---|
| Condition | Nonscarring hair loss associated with GLP-1 receptor agonists |
| Key Mechanisms | Rapid weight loss, alterations in insulin signaling, androgen changes, direct follicular effects |
| Target Population | Adults aged 18 to 89 years and adolescents aged 12 to 17 years treated with GLP-1 RAs |
| Care Setting | Multicenter cohort study using electronic health records |
Key Highlights
- GLP-1 RA users had higher odds of nonscarring hair loss at 6 and 12 months compared to controls.
- At 12 months, odds ratios for telogen effluvium, androgenetic alopecia, and overall hair loss were significant.
- Adolescents showed limited data due to small sample size, highlighting access barriers.
Guideline-Based Recommendations
Diagnosis
- Monitor for nonscarring hair loss in patients prescribed GLP-1 RAs.
Management
- Provide anticipatory guidance regarding hair loss risks.
Monitoring & Follow-up
- Consider prospective monitoring strategies for hair loss in patients on GLP-1 RAs.
Risks
- Increased odds of telogen effluvium and androgenetic alopecia in GLP-1 RA users.
Patient & Prescribing Data
Adults and adolescents using GLP-1 RAs for type 2 diabetes management.
Awareness of alopecia risk is critical for early detection and multidisciplinary care.
Clinical Best Practices
- Educate patients on potential hair loss associated with GLP-1 RA therapy.
- Encourage regular follow-ups to assess hair health in patients on GLP-1 RAs.
References
